Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL

References

• Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–13.
   PubMed Web of Science ®Google Scholar
• Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569–579.
   PubMed Web of Science ®Google Scholar
• Ruiss R, Jochum S, Mocikat R, et al. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells - a new option for the treatment of B-CLL. PLoS One. 2011;6:e25294.
   Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–659.
   PubMed Web of Science ®Google Scholar
• Ruiss R, Jochum S, Wanner G, et al. A virus-like particle-based Epstein-Barr virus vaccine. J Virol. 2011;85:13105–13113.
   PubMed Web of Science ®Google Scholar
• Beauvillain C, Juste MO, Dion S, et al. Exosomes are an effective vaccine against congenital toxoplasmosis in mice. Vaccine. 2009;27:1750–1757.
   PubMed Web of Science ®Google Scholar
• Delcayre A, Estelles A, Sperinde J, et al. Exosome Display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis. 2005;35:158–168.
   PubMed Web of Science ®Google Scholar
• Rountree RB, Mandl SJ, Nachtwey JM, et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011;71:5235–5244.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hong Y, Cho E, et al. Extracellular vesicles as a platform for membrane- associated therapeutic protein delivery. J Extracell Vesicles. 2018;7: 1440131.
   Web of Science ®Google Scholar
• Cramer P, Hallek M, Eichhorst B. State-of-the-art treatment and novel agents in chronic lymphocytic leukemia. Oncol Res Treat. 2016;39:25–32.
   PubMed Web of Science ®Google Scholar
• Morabito F, Recchia AG, Vigna E, et al. Promising therapies for the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2015;24:795–807.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2018;127:208–216.
   Web of Science ®Google Scholar
• Wolos JA, Davey FR. B lymphocyte function in B cell chronic lymphocytic leukaemia. Br J Haematol. 1981;49:395–403.
   PubMed Web of Science ®Google Scholar
• Cantwell M, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984–989.
   PubMed Web of Science ®Google Scholar
• Battle TE, Wierda WG, Rassenti LZ, et al. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003;9:2166–2172.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Rousseau RF, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659–670.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917–2924.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Kofler DM, Mayr C, et al. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma. 2004;45:897–904.
   PubMed Web of Science ®Google Scholar
• Mayr C, Kofler DM, Büning H, et al. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood. 2005;106:3223–3226.
   PubMed Web of Science ®Google Scholar
• Stanfield BA, Luftig MA. Recent advances in understanding Epstein-Barr virus. F1000Res. 2017;6:386.
   Google Scholar
• Tarrand JJ, Keating MJ, Tsimberidou AM, et al. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer. 2010;116:880–887.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Carbone A. Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor? Infect Agent Cancer. 2010;5:22.
   PubMedGoogle Scholar
• Ferrajoli A, Ivan C, Ciccone M, et al. Epstein-Barr virus microRNAs are expressed in patients with chronic lymphocytic leukemia and correlate with overall survival. Ebiom. 2015;2:572–582.
   PubMed Web of Science ®Google Scholar
• Nemerow GR, Wolfert R, Mcnaughton ME, et al. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol. 1985;55:347–351.
   PubMed Web of Science ®Google Scholar
• Vallhov H, Gutzeit C, Johansson S, et al. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol. 2011;186:73–82.
   PubMed Web of Science ®Google Scholar
• Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol. 2004;173:7481–7489.
   PubMed Web of Science ®Google Scholar
• Mackus WJM, Frakking FNJ, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102:1057–1063.
   PubMed Web of Science ®Google Scholar
• Pourgheysari B, Bruton R, Parry H, et al. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood. 2010;116:2968–2974.
   PubMed Web of Science ®Google Scholar
• Te Raa GD, Pascutti MF, García-Vallejo JJ, et al. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014;123:717–724.
   Web of Science ®Google Scholar
• Van Deun J, Mestdagh P, Agostinis P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228–232.
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59–74.
   PubMed Web of Science ®Google Scholar
• Kempkes B, Pich D, Zeidler R, et al. Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci U S A. 1995;92:5875–5879.
   Web of Science ®Google Scholar
• Théry C, Clayton A, Amigorena S, et al. Isolation and characterization of exosomes from cell culture supernatants. Curr Protoc Cell Biol. 2006;Chapter 3:Unit3.22.
   Google Scholar
• Kater AP, Remmerswaal EBM, Nolte MA, et al. Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol. 2004;126:512–516.
   PubMed Web of Science ®Google Scholar
• Moosmann A, Khan N, Cobbold M, et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood. 2002;100:1755–1764.
   Web of Science ®Google Scholar
• Biagi E, Rousseau R, Yvon E, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11:6916–6923.
   PubMed Web of Science ®Google Scholar
• Messmer D, Kipps TJ. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005;1062:51–60.
   PubMed Web of Science ®Google Scholar
• Wendtner C, Kofler DM, Theiss HD, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2013;100:1655–1661.
   Web of Science ®Google Scholar
• Steininger C, Rassenti LZ, Vanura K, et al. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest. 2009;39:497–506.
   Web of Science ®Google Scholar
• Vanura K, Rieder F, Kastner M, et al. Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One. 2013;8:1–12.
   Web of Science ®Google Scholar
• Keller SA, von Allmen CE, Heather J, et al. Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles. J Immunol. 2009;182:6261–6266.
   Web of Science ®Google Scholar
• Hon H, Oran A, Brocker T, et al. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol. 2005;174:5233–5242.
   PubMed Web of Science ®Google Scholar